Review
Bi-specific antibody therapy for the treatment of cancer
Affiliations
- PMID: 11249732
Item in Clipboard
Review
Bi-specific antibody therapy for the treatment of cancer
Curr Opin Mol Ther.
2001 Feb.
Abstract
Bi-specific antibodies (BsAbs) combine immune cell activation with tumor cell recognition as a result of which tumor cells are killed by pre-defined effector cells. In this review a brief introduction to monoclonal antibodies will precede a more in-depth presentation of the current status of BsAb therapy for cancer. Target molecules and effector mechanisms aimed at tumor cells or aimed at tumor vasculature, and the application of recombinant DNA technology in the construction of antibodies, will be discussed. The lessons learned from the last decade will be discussed in consideration of the potential future development of BsAbs for cancer therapy.
Similar articles
-
Recombinant bispecific antibodies for cellular cancer immunotherapy.Curr Opin Mol Ther. 2007 Aug;9(4):319-26. Curr Opin Mol Ther. 2007. PMID: 17694444 Review.
-
Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.BioDrugs. 2013 Feb;27(1):35-53. doi: 10.1007/s40259-012-0008-z. BioDrugs. 2013. PMID: 23329400 Review.
-
Recombinant bispecific antibodies for cancer therapy.Acta Pharmacol Sin. 2005 Jan;26(1):1-9. doi: 10.1111/j.1745-7254.2005.00008.x. Acta Pharmacol Sin. 2005. PMID: 15659107 Review.
-
Tumor-antigen-binding bispecific antibodies for cancer treatment.Semin Oncol. 2014 Oct;41(5):653-60. doi: 10.1053/j.seminoncol.2014.08.004. Epub 2014 Aug 12. Semin Oncol. 2014. PMID: 25440609 Review.
-
Recent advances in the generation of bispecific antibodies for tumor immunotherapy.Curr Opin Drug Discov Devel. 2004 Mar;7(2):233-42. Curr Opin Drug Discov Devel. 2004. PMID: 15603258 Review.
Cited by
-
Targeting cancers through TCR-peptide/MHC interactions.J Hematol Oncol. 2019 Dec 18;12(1):139. doi: 10.1186/s13045-019-0812-8. J Hematol Oncol. 2019. PMID: 31852498 Free PMC article. Review.
-
Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9051-6. doi: 10.1073/pnas.0403222101. Epub 2004 Jun 7. Proc Natl Acad Sci U S A. 2004. PMID: 15184663 Free PMC article.
-
Preclinical evaluation of light-activatable, bispecific anti-human CD3 antibody conjugates as anti-ovarian cancer therapeutics.MAbs. 2009 Jul-Aug;1(4):348-56. doi: 10.4161/mabs.1.4.9045. Epub 2009 Jul 19. MAbs. 2009. PMID: 20068406 Free PMC article.
-
FLT3 antibody-based therapeutics for leukemia therapy.Int J Hematol. 2005 Aug;82(2):108-14. doi: 10.1532/IJH97.05068. Int J Hematol. 2005. PMID: 16146840 Review.
-
Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9421-6. doi: 10.1073/pnas.132285699. Epub 2002 Jul 1. Proc Natl Acad Sci U S A. 2002. PMID: 12093904 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources